Amyloid a amyloidosis secondary to rheumatoid arthritis: Pathophysiology and treatment

Clinical and Experimental Rheumatology

Volumn 29, Issue 5, 2011, Pages 850-857

  Nakamura, T ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Amyloidosis; Biologies; Inflammation mediators; Rheumatoid arthritis; Serum amyloid A protein

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; DIMETHYL SULFOXIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPRODISATE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SERUM AMYLOID A; TACROLIMUS; TOCILIZUMAB;

ALLELE; AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; GENETIC PREDISPOSITION; HEMODIALYSIS; HEREDITY; HUMAN; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

AMYLOIDOSIS; ARTHRITIS, RHEUMATOID; HUMANS; SERUM AMYLOID A PROTEIN;

EID: 83455173669     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. WESTERMARK GT, WESTERMARK P: Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett 2009; 583: 2685-90.
2. OBICI L, RAIMONDI S, LAVATELL F, BELLOTTI V, MERLINI G: Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009; 61: 1435-40.
3. KOIVUNIEMI R, PAIMELA L, SUOMALAINEN R, LEIRISALO-REPO M: Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 408-13. (Pubitemid 352003208)
4. NAKAMURA T: Amyloid A amyloidosis secondary to rheumatoid arthritis: an uncommon yet important complication. Curr Rheumatol Rev 2007; 3: 231-41. (Pubitemid 47335352)
5. UHLAR CM, WHITEHEAD AS: Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-23. (Pubitemid 29488982)
6. ROCKEN C, SHAKESPEARE A: Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002; 440: 111-22. (Pubitemid 34169846)
7. KLUVE-BECKERMAN B, MANALOOR J, LIEPNIEKS JJ: Binding, trafficking and accumulation of serum amyloid A in peripheral macrophages. Scand J Immunol 2001; 53: 393-400. (Pubitemid 32275697)
8. KISILEVSKY R: Amyloidogenesis-unquestioned answers and unanswered questions. J Struct Biol 2000; 130: 99-108.
9. TAKAHASHI M,YOKOTA T,KAWANO H,GONDO T, ISH1HARA T, UCH1NO F: Ultrastructual evidence for intracellular formation of amyloid fibrils in macrophages. Virchows Arch 1989;415:411-9. (Pubitemid 19241013)
10. KLUVE-BECKERMAN B, MANALOOR JJ, LIEPNICKS JJ: A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum 2002; 46: 1905-13. (Pubitemid 34774523)
11. MAGY N, BENSON MD, LIEPNICKS JJ, KLUVE-BECHERMAN B: Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model. Amyloid 2007; 14: 51-63. (Pubitemid 46491169)
12. LUNDMARK K, WESTERMARK GT, NYSTROM S, MURPHY CL, SOLOMON A, WESTERMARK P: Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 2002; 99: 6979-84. (Pubitemid 34526243)
13. ENQVIST S, SLETTEN K, WESTERMARK P: Fibril protein fragmentation pattern in systemic AL-amyloidosis. J Pathol 2009; 219: 473-80.
14. ANCSIN JB, KISILEVSKY R: The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999;274:7172-81.
15. ELIMOVA E, KISILEVSKY R, SZAREK WA, ANCSIN JB: Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004; 18: 1749-51. (Pubitemid 39561672)
16. VAN DER HILST JCH, YAMADA T, OP DEN CAMP HJ. VAN DER MEER JW, DRENTH JP, SIMON A: Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford) 2008; 47: 1651-4.
17. VAN DER HILST JCH, KLUVE-BECHERMAN B, VAN DER MEER JWM, SIMON A: Cathepsin D activity protects against development of type AA amyloid fibrils. Eur J Clin Invest 2009; 39:412-6.
18. MAURY CPJ, AITTONIEMI J, TIITINEN S, LAIHO K, KAARELA K, HURME M: Variant mannose-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. J Intern Med 2007; 262: 466-9. (Pubitemid 47404366)
19. GARRED P, LARSEN F, SEYFARTH J, FUJITA R, MADSEN HO: Mannose-binding lectin and its genetic variants. Genes Immun 2006; 7: 85-94. (Pubitemid 43336050)
20. MIGITA K, YAMASAKI S, SHIB ATOMI K et al:. Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Immunol 2001; 123: 408-11. (Pubitemid 32289959)
21. LUNDMARK K, WESTERMARK GT, OLSEN A, WESTERMARK P: Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: cross-seeding as a disease mechanism. Proc Natl Acad Sci USA 2005; 102: 6098-102. (Pubitemid 40594261)
22. VAN DER HILST JC, KLUVE-BECKERMAN B, BODAR EJ, VAN DER MEER JW, DRENTH JP, SIMON A: Lovastatin inhibits formation of AA amyloid. J Leukoc Biol 2008; 83: 1295-9. (Pubitemid 351960362)
23. BERGESIO F, CICIANI AN, MANGANARO M et al.: Renal involvement in systemic amyloidosis. Nephrol Dial Transplant 2008; 23: 941-51. (Pubitemid 351767556)
24. CALAMAI M, KUMITA JR, MIFSUD J et al.: Nature and significance of the interactions between amyloid fibrils and biological polyelectrolytes. Biochemistry 2006; 45: 12806-15. (Pubitemid 44630867)
25. TENNENT GA, LOVAT MB, PEPYS MB: Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995; 92: 4299-303.
26. UDA H, YOKOTA A, KOBAYASHI K et al.: Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol 2006; 33: 1482-7. (Pubitemid 44168816)
27. SATTIANAYAGAM PT, HAWKINS PN, GILLMORE JD: Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2009;6:608-17.
28. MALLE E, STEINMETZ A, RAYNES JG: Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 1993; 102: 131-46. (Pubitemid 23283948)
29. POITOU C, VIGUERIE N, CANCELLO C et al.: Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005; 48: 519-28. (Pubitemid 40487299)
30. YAMADA T, SATO J, OKUDA Y: Differential affinity of serum amyloid Al isotypes for high-density lipoprotein. Amyloid 2009; 16: 196-200.
31. XU Y, YAMADA T, SATOH T, OKUDA Y: Measurement of serum amyloid A1 (SAA 1), a major isotype of acute phase SAA. Clin Chem Lab Med 2006; 44: 59-63. (Pubitemid 43010647)
32. AJIRO J, NARITA I, SATO S et al.: SAA1 gene polymorphisms and the risk of AA amyloidosis on Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006; 16: 294-9. (Pubitemid 44575255)
33. BARANOVA IN, VISHNYAKOVA TG, BOCHAROV AV et al.: Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem 2005; 280:8031-40. (Pubitemid 40349701)
34. HE R, SANG H, YE RD: Serum amyloid A induces IL-8 secretion through a G proteincoupled receptor, FPRL1/LXA4R. Blood 2003; 101: 1572-81. (Pubitemid 36182537)
35. WALDER K, KANTHAM L, MCMILLAN JS et al.: Tanis: a link between type 2 diabetes and inflammation? Diabetes 2002; 51: 1859-66. (Pubitemid 34564299)
36. SANDRI S, RODRIGUES D, GOMES E, MONTEIRO HP, RUSSO M, CAMPA A: Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 2008; 83: 1174-80. (Pubitemid 351960349)
37. HE RL, ZHOU J, HANSON CZ, CHEN J,CHENG N, YE RD: Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009; 113: 429-37.
38. TANAKA N, YONEKURA H, YAMAGISHI S, FUJIMORI H, YAMAMOTO Y, YAMAMOTO H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-a through nuclear factor α, and 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 33: 25781-90.
39. ROCKEN C.KIENTSCH-ENGEL R.MANSFELD S et al.: Advance glycation end products and receptor for advanced glycation end products in AA amyloidosis. Am J Pathol 2003; 162: 1213-20. (Pubitemid 36350665)
40. OKAMOTO H, KATAGIRI Y, KIIRE A, MOMOHARA S, KAMATANI M: Serum amyloid A activates nuclear factor-KB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. J Rheumatol 2008; 35: 752-6. (Pubitemid 351747112)
41. MULLAN RH, MCCORMICK J, CONNOLLY M, BRESNIHAN B, VEALE DJ, FEARON U: A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A. Am J Pathol 2010; 176: 1999-2008.
42. LEE HY, KIM SD, SHIM JW et al.: Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J Immunol 2008; 181: 4332-9.
43. YAN SD, ZHU H, ZHU A et al.: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6:643-51. (Pubitemid 30398787)
44. MIGITA K, ABIRI S, NAKAMURA M et al.: Lipopolysaccharide signaling induces serum amyloid A (SAA) synthesis in human hepatocytes in vitro. FEBS Lett 2004; 569: 235-9. (Pubitemid 38844624)
45. HATANAKA E, FURLANETO CJ, RIBEIRO FP, SOUZA GM, CAMPA A: Serum amyloid Ainduced mRNA expression and release of tumor necrosis factor-alpha (TNF-alpha) in human neutrophils. Immunol Lett 2004; 91: 33-7. (Pubitemid 38147743)
46. VALLON R, FREULER F, DESTA-TSEDU N et al.: Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol2001; 166: 2801-7. (Pubitemid 32173521)
47. BABA S, MASAGO SA, TAKAHASHI T et al.: A novel allelic variant of serum amyloid A, SAAlγ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995; 4: 1083-7.
48. NAKAMURA T, HIGASHI S, TOMODA K, TSUKANO M, BABA S, SHONO M: Significance of SAA 1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 43-9. (Pubitemid 43033873)
49. UTKU U, DILEK M, AKPOLAT I, BEDIR A, AKPOLAT T: SAAI α/α alleles in Behçet's disease related amyloidosis. Clin Rheumatol 2007; 26: 927-9. (Pubitemid 46951291)
50. MORIGUCHI M, KANEKO H, TERAI C et al.: Relative transcriptional activities of SAAI promoters polymorphic at position -13(T/C): potential association between increased transcription and amyloidosis. Amyloid 2005; 12: 26-32. (Pubitemid 40896941)
51. TURESSON C, WEYAND CM, MATTESON EL: Genetics of rheumatoid arthritis: is there a pattern predicting extraarticular manifestations? Arthritis Rheum 2004; 51: 853-63. (Pubitemid 39372045)
52. MIGITA K, NAKAMURA T, MAEDA Y et al.: HLA-DRB1 04 alleles in Japanese rheuma-toid arthritis patients with AA amyloidosis. J Rheumatol 2006; 33: 2120-3. (Pubitemid 44749767)
53. KOIVUNIEMI R, PAIMELA L, SUOMALINEN R, TORNROTH T, LEIRISALO-REPO M: Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15: 262-8.
54. GOMEZ-CASANOVAS E, SANMARTI R, SOLE M, CANATE JD, MUNOZ-GOMEZ J: The clinical significance of amyloid fat deposit in rheumatoid arthritis. A systemic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001; 44: 66-72. (Pubitemid 32113120)
55. ISHII W, MATSUDA M, NAKAMURA A, NAKAMURA N, SUZUKI A, IKEDA S: Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 2003; 42: 800-5. (Pubitemid 37258692)
56. WAKHLU A, KRISNAN1 N, HISSATIA P, AGGARWAL A, MISRA R: Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 2003;30:948-51. (Pubitemid 36529612)
57. EL MANSOURY TM, HAZENBERG BP, EL BADAWY SA et al:. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 2002; 61:42-7. (Pubitemid 34074838)
58. GONZALEZ-ALVARO I, CARMONA L, BALSA A, SANMARTI R, BELMONTE MA, TENA X: Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003; 30: 697-704. (Pubitemid 36402760)
59. MISRA R, WAKHLU A, KRISHNAMI N, HISSARIA P. AGGARWAL A: Prevalence of silent amyloidosis in rheumatoid arthritis and its clinical significance. J Rheumatol 2004; 31: 1031-4.
60. LACHMANN HJ, GOODMAN HJ, GILBERTSON JA et al.: Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71. (Pubitemid 46883770)
61. KOBAYASHI H, TADA S, FUCHIGAMIT et al.: Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 1996; 35: 44-9.
62. ISHII W, MATSUDA M, NAKAMURA N et al.: Phenol Congo red staining enhances the diagnostic value of abdominal fat aspiration biopsy in reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 2003; 42: 400-5. (Pubitemid 36701562)
63. GILLMORE JO, LEVITT LB, JERSEY MA, PEPYS MB, HAWKINS PN: Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-9. (Pubitemid 32709735)
64. MASUTANI K, NAGATA M, IKEDA H et al.: Glomerular crescent formation in renal amyloidosis. A clinicopathological study and demonstration of upregulated cell-mediated immunity. Clin Nephrol 2008; 70: 464-74.
65. NAKAMURA T: Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2008; 18: 109-18.
66. PETTERSSON T, KONTTINEN YT, MAURY CPJ: Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 2008; 9: 2117-28.
67. DEMBER LM: Modern treatment of amyloidosis: unresolved questions. J Am Soc Nephrol 2009; 20: 469-72.
68. PERFETTO F, MOGGI-PIGNONE A, LIVI R, TEMPESTINI A, BERGESIO F, MATUCCI-CERINIC M: Systemic amyloidosis: a challenge for the rheumatologist. Afar Rev Rheumatol 2010; 6: 417-29.
69. KURODA T, WADA Y, KOBAYASHI D et al.: Effective anti-TNF-α therapy can induce rapid resolution and sustained decrease of gastrointestinal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 2009; 36: 2409-15.
70. NAKAMURA T, HIGASHI S, TOMODA K, TSUKANO M, SHONO M: Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2010; 29: 1395-401.
71. NAKAMURA T, HIGASHI S, TOMODA K, TSUKANO M, BABA S: Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 2007;25:518-22. (Pubitemid 47455459)
72. OKUDA Y, TAKASUGI K: Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54: 2997-3000. (Pubitemid 44497781)
73. NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebocontrolled trial. Arthritis Rheum 2004; 50: 1761-9. (Pubitemid 38725087)
74. HAGIWARA K, NISHIKAWA T, ISOBET, SONG J, SUGAMATA Y, YOSHIZAKI K: 11-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314: 363-9. (Pubitemid 38084725)
75. KISHIMOTOT.AKIRAS.TAGAT: IL-6 receptor and mechanism of signal transduction. Int J Immunopharmacol 1992; 14: 431-8.
76. HIRANO T, ISHIHARA K, HIBI M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-56. (Pubitemid 30339210)
77. HAGIHARA K, NISHIKAWA T, SUGAMATA Y et al.: Essential role of STAT3 in cytokinedriven NF-κB-mediated serum amyloid A gene expression. Gene Cells 2005; 10: 1051-63. (Pubitemid 41556074)
78. UEDA M, ANDO Y, NAKAMURA M et al:. FK506 inhibits murine AA amyloidosis: possible involvement of T cells in amyloidogenesis. J Rheumatol 2006; 33: 2260-70. (Pubitemid 44749787)
79. KOGINA K, SHODA H, YAMAGUCHI Y et al.: Tacrolimus differentially regulates the proliferation of conventional and regulatory CD4 T cells. Mot Cells 2009; 28: 125-30.
80. DEMBER LM, HAWKINS PN, HAZENBERG BP et al:. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356: 2349-60. (Pubitemid 46883769)
81. PEPYS MB, HERBERT J, HUTCHINSON L et al.: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254-9. (Pubitemid 34534701)
82. SANTOS NC, FIGUERIA-COELHO J, MARTINS-SILVA J, SALDANHA C: Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003; 65: 1035-41. (Pubitemid 36349743)
83. AMEMORI S, IWAKIRI R, ENDO H et al.: Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J Gastroenterol 2006; 41: 444-9. (Pubitemid 43941911)
84. KURODA T, TANABE N, SATO H et al: Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment. Rheumatol Int 2006; 26: 1147-53. (Pubitemid 44450853)
85. NAKAMURA T, HIGASHI S, TOMODA K, TSUKANO M, ARIZONO K, NAKAMURA T: Etanercept treatment in patients with rheumatoid arthritis on dialysis. Rheumatol Int 2010; 30: 1527-8.
86. DON BR, SPIN G, NESTOROV I, HUTMACHER M, ROSE A, KAYSEN GA: The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 2005; 57: 1407-13. (Pubitemid 350066982)
87. SAKKA T, ABELSON B, PINCUS T: Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26: S35-61.
88. SATTAR N, MCCAREY DW, CAPELL H, McINNES IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63. (Pubitemid 37553561)
89. URIELI-SHOVAL S, LINKE RP, MATZNER Y: Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000; 7: 64-9. (Pubitemid 30007690)
90. NAKAMURA T, TOMODA K, TSUKANO M, YAMAMURA Y, BABA S: Gustatory sweating due to autonomic neuropathy in a patient with amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2004; 14: 498-501. (Pubitemid 40028678)